NASDAQ:BYSI - Beyondspring Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $20.40 +0.20 (+0.99 %) (As of 12/16/2018 12:02 PM ET)Previous Close$20.40Today's Range$20.11 - $20.7052-Week Range$16.15 - $34.00Volume13,583 shsAverage Volume5,842 shsMarket Capitalization$457.69 millionP/E Ratio-4.64Dividend YieldN/ABeta1.33 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. BeyondSpring Inc. was founded in 2010 and is headquartered in New York, New York. Receive BYSI News and Ratings via Email Sign-up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BYSI Previous Symbol CUSIPN/A Webwww.beyondspringpharma.com Phone1-646-305-6387 Debt Debt-to-Equity RatioN/A Current Ratio4.36 Quick Ratio4.36 Price-To-Earnings Trailing P/E Ratio-4.64 Forward P/E Ratio-9.07 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.23 per share Price / Book16.59 Profitability EPS (Most Recent Fiscal Year)($4.40) Net Income$-91,760,000.00 Net MarginsN/A Return on Equity-248.70% Return on Assets-199.47% Miscellaneous Employees38 Outstanding Shares22,440,000Market Cap$457.69 million OptionableNot Optionable Beyondspring (NASDAQ:BYSI) Frequently Asked Questions What is Beyondspring's stock symbol? Beyondspring trades on the NASDAQ under the ticker symbol "BYSI." How were Beyondspring's earnings last quarter? Beyondspring Inc (NASDAQ:BYSI) released its quarterly earnings data on Tuesday, October, 23rd. The company reported ($0.54) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.08. View Beyondspring's Earnings History. When is Beyondspring's next earnings date? Beyondspring is scheduled to release their next quarterly earnings announcement on Tuesday, April 2nd 2019. View Earnings Estimates for Beyondspring. What price target have analysts set for BYSI? 2 analysts have issued 12-month price objectives for Beyondspring's shares. Their forecasts range from $35.00 to $60.00. On average, they expect Beyondspring's stock price to reach $47.50 in the next twelve months. This suggests a possible upside of 132.8% from the stock's current price. View Analyst Price Targets for Beyondspring. What is the consensus analysts' recommendation for Beyondspring? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beyondspring in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Beyondspring. What are Wall Street analysts saying about Beyondspring stock? Here are some recent quotes from research analysts about Beyondspring stock: 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $60 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, Plinabulin. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (12/6/2018) 2. According to Zacks Investment Research, "BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company's lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. " (10/26/2018) 3. Maxim Group analysts commented, "BeyondSpring reported 3Q18 (on 10/23) with expenses of $12.4M. The company ended the period with a cash balance of $22.4M. The company has runway into early 2019 though we expect BYSI needs to raise capital. Combined with the recent pullback in valuation, driven in part by macro factors such as contracting multiples in the healthcare space, we lower our price target to $35, from $48 – still plenty of upside." (10/25/2018) Has Beyondspring been receiving favorable news coverage? News stories about BYSI stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Beyondspring earned a daily sentiment score of 1.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days. Who are some of Beyondspring's key competitors? Some companies that are related to Beyondspring include Ironwood Pharmaceuticals (IRWD), Reata Pharmaceuticals (RETA), Zogenix (ZGNX), Innoviva (INVA), Madrigal Pharmaceuticals (MDGL), PTC Therapeutics (PTCT), Prestige Consumer Healthcare (PBH), Mallinckrodt (MNK), Biohaven Pharmaceutical (BHVN), Theravance Biopharma (TBPH), Wave Life Sciences (WVE), Enanta Pharmaceuticals (ENTA), The Medicines (MDCO), Cambrex (CBM) and Vanda Pharmaceuticals (VNDA). Who are Beyondspring's key executives? Beyondspring's management team includes the folowing people: Dr. Lan Huang, Co-Founder, Chairman & CEO (Age 47)Mr. Dongheng Liu, Chief Financial Officer (Age 36)Mr. Richard J. Daly, Chief Operating Officer (Age 57)Ms. Amy Yang, ControllerDr. Ramon W. Mohanlal, Chief Medical Officer of BeyondSpring U.S. (Age 60) When did Beyondspring IPO? (BYSI) raised $4 million in an initial public offering on Thursday, March 9th 2017. The company issued 200,000 shares at a price of $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) served as the underwriter for the IPO. Who are Beyondspring's major shareholders? Beyondspring's stock is owned by a number of of retail and institutional investors. Top institutional investors include Tanaka Capital Management Inc. (0.22%). Which institutional investors are buying Beyondspring stock? BYSI stock was purchased by a variety of institutional investors in the last quarter, including Tanaka Capital Management Inc.. How do I buy shares of Beyondspring? Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Beyondspring's stock price today? One share of BYSI stock can currently be purchased for approximately $20.40. How big of a company is Beyondspring? Beyondspring has a market capitalization of $457.69 million. The company earns $-91,760,000.00 in net income (profit) each year or ($4.40) on an earnings per share basis. Beyondspring employs 38 workers across the globe. What is Beyondspring's official website? The official website for Beyondspring is http://www.beyondspringpharma.com. How can I contact Beyondspring? Beyondspring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 1-646-305-6387 or via email at [email protected] MarketBeat Community Rating for Beyondspring (NASDAQ BYSI)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 119 (Vote Outperform)Underperform Votes: 109 (Vote Underperform)Total Votes: 228MarketBeat's community ratings are surveys of what our community members think about Beyondspring and other stocks. Vote "Outperform" if you believe BYSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BYSI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/16/2018 by MarketBeat.com StaffFeatured Article: What is Depreciation?